Oncology News | pharmaphorum

News

Trial flop busts Deciphera's blockbuster hopes for Qinlock

Shares in Deciphera Pharma went into freefall on Friday after top-line results of a phase 3 trial of its Qinlock in rare cancer gastrointestinal stromal tumour (GIST) dashed its hopes of mo

News

EMA starts review of Enhertu for HER2+ gastric cancer

The EMA has started its review of AstraZeneca and Daiichi Sankyo's Enhertu for a second indication, as a second-line treatment for HER2-positive gastric cancer.

News

First launch for Daiichi Sankyo's oncolytic virus Delytact i...

Daiichi Sankyo has launched its oncolytic virus therapy Delytact in Japan – its first world market – as a treatment for malignant glioma, an aggressive form of brain cancer.

News

Novartis' 'wild card' drug Scemblix gets FDA nod for leukaem...

Novartis has claimed FDA approval for one of its 'wild card' drugs – Scemblix – a first-in-class STAMP inhibitor for patients with previously-treated chronic myeloid leukaemia (CML).

News

Gilead tags Merck for first-line triple negative breast canc...

Take two recently-approved immunotherapies for triple negative breast cancer (TNBC), put them together, and what do you get?

News

AZ/Daiichi partner with Merck on first-line lung cancer tria...

The dominance of Merck & Co's Keytruda in the treatment of previously-untreated non-small cell lung cancer (NSCLC) means it will be hard to dislodge – so AstraZeneca and Daiichi Sankyo

Trial flop busts Deciphera's blockbuster hopes for Qinlock

EMA starts review of Enhertu for HER2+ gastric cancer

First launch for Daiichi Sankyo's oncolytic virus Delytact i...

Novartis' 'wild card' drug Scemblix gets FDA nod for leukaem...

Gilead tags Merck for first-line triple negative breast canc...

AZ/Daiichi partner with Merck on first-line lung cancer tria...

Vanda ends 40-year hiatus for new motion sickness drugs

How to meet your physicians where they are online

News

Editor's Picks